Latest research on Olanzapine

Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.

Latest findings

In the present study, we have used PCP and Amphetamine in the paired click paradigm in conscious rats i) to model disturbances in the AEP waveform components observed in schizophrenia and ii) to evaluate the degree to which the mGluR2 agonist LY404039 [48] and the PDE10 inhibitor PQ-10 [51] could improve PCP and Amphetamine-induced auditory processing deficits as was observed with atypical antipsychotics Risperidone and Olanzapine, respectively. [source, 2016]
The test drugs were Risperidone (0.64 mg/kg), Olanzapine (2.5 mg/kg), LY403939 (10 mg/kg) and PQ-10 (3 mg/kg). [source, 2016]
The doses of Risperidone and Olanzapine were selected based on Dopamine D2 receptor occupancy and their potency to attenuate the challenge-induced hyperlocomotor behaviour. [source, 2016]
Subsequently, it was determined to what extent the atypical antipsychotics Risperidone (0.64 mg/kg) and Olanzapine (2.5 mg/kg) would normalize PCP and amphetamine-induced aberrant AEP waveform components and EEG oscillations, respectively. [source, 2016]
All drugs were synthesized at Janssen Research and Development laboratories and were prepared and administered as follow: Risperidone and Olanzapine (H2O + 2H2T + NaCl, subcutaneous), PCP and Amphetamine (H2O + NaCl, subcutaneous). [source, 2016]
Olanzapine, which exhibits a potent antagonist activity at the 5-HT2 receptor, elevated the amplitude response S1 stimuli suggesting an opposite effect might restore deficits of P50 suppression in rodents [54]. [source, 2016]
In accordance with this model, the present work demonstrated that both atypical antipsychotics Risperidone and Olanzapine increased peak amplitudes to S1 stimuli and attenuated Amphetamine and PCP-induced altaerations in AEP peak amplitudes, respectively. [source, 2016]
In line with these observations, pretreatment with the atypical antipsychotics Risperidone and Olanzapine consistently reduced PCP and amphetamine-induced transient pathological enhanced higher gamma and alpha frequency oscillations. [source, 2016]
Neuroleptics (e.g., Olanzapine) could reduce the seizure threshold to a lesser extent compared with clozapine; some antidepressants—mainly selective serotonin reuptake inhibitors—might have the opposite effect and actually increase the seizure threshold (Alper et al., 2007; Tebartz van Elst and Perlov, 2013). [source, 2016]
Concerning medication, three patients were free of any antipsychotic medication, the others received mono- or dual therapy with atypical antipsychotic medication including Amisulpride (n = 2), Olanzapine (n = 11), Clozapine (n = 4), Quetiapine (n = 2), Ziprasidone (n = 1), Risperidone (n = 5), Aripiprazole (n = 2), Paliperidone (n = 3; cp. [source, 2016]